Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for LAVA Therapeutics N.V. (LVTX : NSDQ)

• Company Description    LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands. Number of Employees: 34

• Price / Volume Information    Yesterday's Closing Price: $1.61 Daily Weekly Monthly 20 Day Moving Average: 480,954 shares Shares Outstanding: 26.31 (millions) Market Capitalization: $42.35 (millions) Beta: 0.50 52 Week High: $2.00 52 Week Low: $0.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.87% 1.15% 12 Week 5.92% 1.53% Year To Date 69.29% 47.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL YALELAAN 62 - UTRECHT,P7 3584 CM NLD ph: 31-85-016-3100 fax: - ir@lavatherapeutics.com http://www.lavatherapeutics.com

• General Corporate Information    Officers Stephen Hurly - Chief Executive Officer; President and Director Kapil Dhingra - Chair of the Board of Directors Fred Powell - Chief Financial Officer Jay Backstrom - Director Peter Kiener - Director Peer Information LAVA Therapeutics N.V. (CORR.) LAVA Therapeutics N.V. (RSPI) LAVA Therapeutics N.V. (CGXP) LAVA Therapeutics N.V. (BGEN) LAVA Therapeutics N.V. (GTBP) LAVA Therapeutics N.V. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: N51517105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/27/26 Share - Related Items Shares Outstanding: 26.31 Most Recent Split Date: (:1) Beta: 0.50 Market Capitalization: $42.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.30% vs. Previous Quarter: 15.62% Sales Growth vs. Year Ago Period: 1,313.60% vs. Previous Quarter: -% ROE 09/30/25 - -107.63 06/30/25 - -106.29 03/31/25 - -86.38 ROA 09/30/25 - -35.06 06/30/25 - -38.24 03/31/25 - -34.12 Current Ratio 09/30/25 - 12.27 06/30/25 - 10.78 03/31/25 - 6.73 Quick Ratio 09/30/25 - 12.27 06/30/25 - 10.78 03/31/25 - 6.73 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -450.92 06/30/25 - -552.14 03/31/25 - -545.07 Book Value 09/30/25 - 0.48 06/30/25 - 0.76 03/31/25 - 0.98 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©